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Aim: Review of recent advances and vision for future developments in clinical practice of
Radiation Oncology.
Background: There have been substantial research and technological developments in Radi-
ation  Oncology over the past 40 years.
Materials and methods: The relevant literature was reviewed and the authors offer their per-
spective on future opportunities for advancement in Radiation Oncology.
Conclusions: Signiﬁcant innovative technological developments have been introduced in the
practice of Radiation Oncology, with more precise target delineation and tracking and three
dimensional treatment planning, optimal delivery of radiation therapy to the target and
lower doses to surrounding Organs at Risk. This dose optimization and adaptive therapyhave enhanced the role of Radiation Therapy to more effectively treat patients with cancer.
Further creativity and reﬁnements will continue to advance the ﬁeld into new applications
of  ionizing radiations in cancer therapy.
© 2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All.  Introduction
adiation Oncology is one of the pillars of multidisciplinary
are of the patient with cancer. In the past 50 years, and
specially the last 20, Radiation Oncology has experienced
ramatic technological innovations (Fig. 1), leading to image-
ased complex three-dimensional treatment planning and
elivery of radiation therapy, using 3D-Conformal or Intensity
odulated Radiation therapy (IMRT), with increased precision
n dose delivered to the target volume(s), while sparing adja-
ent normal structures (Organs at Risk, OAR).1 The dose-rate
ffect of external beam radiation therapy with conventional
inear accelerators is governed by the overall beam-on-time.
ith the advent of ﬂattening-ﬁlter-free accelerators and
ypofractionation (high dose per fraction) radiation therapy
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schemas, biological effects of external beam dose rate will
need further investigation.2
2.  Treatment  planning  and  dosimetry
Requirements on dose conformality, smaller PTV margins and
the sharp peripheral dose gradient of these techniques require
a more  stringent Quality Assurance Program. Widespread use
of electronic clinical and dosimetry records and informatics
methodology will add reliability to the data acquired. Expo-
nential growth of medical imaging modalities (CT, MRI, US), 65804, USA. Tel.: +1 314 910 7095.
including image  fusion have enhanced our ability to diag-
nose cancer at earlier stages and to more  accurately stage
the tumor. The improvement in staging accuracy has enabled
us to better tailor therapy based on the characteristics and
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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sis oFig. 1 – Evolution in ba
the extent of the individual patient’s tumor. In the past 10
years there has been an increasing use of functional PET
imaging (18F-FDG or other speciﬁc radiotracers for hypoxia,
cellular proliferation, angiogenesis, etc.) or magnetic reso-
nance spectrometry, with better delineation of target volumes,
particularly clinical target volumes.3
3.  In-Room  imaging
In-Room on-line imaging devices, including Cone-Beam CT
(CBCT), commercially available have facilitated the implemen-
tation of Image-Guided Radiation Therapy (IGRT). Implanted
target tracking devices enhance our ability to more  accurately
localize the target for treatment. 4D CT scanning with faster
scanners and treatment planning has facilitated correction
of target motion in the lung and upper abdomen, including
Active Breathing Control Techniques. As a corollary, stereo-
tactic hypofractionated techniques have been introduced in
the treatment of brain, lung, and tumors in other anatomical
sites.
While the CBCT and these other technologies have come
a long way, we  are still unable to image  and quantify the
true extent of soft tissue tumors on daily basis and during
the radiation delivery. This undoubtedly remains one of the
last frontiers in Radiation Oncology and the recent techno-
logical developments and research indicate that we will have
these capabilities in the upcoming years. Internal implantable
electromagnetic or transmission dosimeters may eventually
facilitate the veriﬁcation of actual radiation dose administered
to the target and OAR.As to the future, we envision an active role of Radiation
Therapy in combination with cytotoxic or biological agents.
While the effect on the tumor may be enhanced, so will be the
sequelae in OAR. This will require more  rigorous treatmentf Radiation Oncology.
planning and Quality Assurance, to diminish toxicity and
unintended radiation effects.
4.  Molecular  biology  and  genomics
The application of genetic proﬁling and DNA mapping, already
used by Medical Oncologists to select patients that will
respond to a speciﬁc antitumor agent or to protect normal
tissues may eventually be introduced in the practice of Radia-
tion Oncology.4 A Holy Grail of research in Radiation Oncology
is the identiﬁcation of speciﬁc genes or molecular markers
to both to predict response of tumors or normal tissues to a
prescribed dose of irradiation.
For the past 50 years in some tumors combinations of cyto-
toxic agents and radiation therapy have improved outcomes in
many  patients. In the future combining genetically engineered
biological agents or molecular compounds may enhance the
effects of radiation therapy on some cancers.
Regardless of the radiation modality we must strive to opti-
mize dosimetric precision, in radiation treatment planning,
delivery and veriﬁcation. One of the key elements in delivery of
radiation therapy that is still to be attained is accurate assess-
ment of the true dose, DA, delivered to the patient. Despite all
of the advances in treatment planning, imaging, and deliv-
ery, the true impact of dynamic nature of cancer patients
(inter and intra fraction motion and patient changes) remains
unknown for the majority of radiation therapy patients.5 The
existing and upcoming developments including: fast image
acquisitions for daily treatments as well as during the actual
radiation delivery, auto contouring and deformable contour
propagation, and fast dose calculations will enable much bet-
ter quantiﬁcation of the DA. The knowledge of DA will enable
further optimization of tradeoffs between doses delivered to
tumor volumes and those delivered to Organs at Risk. A better
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nderstanding of the limits for these tradeoffs will enable
xploration of the true limits of radiation therapy effective-
ess and will guide future developments in technology and
rocedures.
.  Future  advances
edical Imaging will continue its vertiginous progress with
dditional reﬁnements, molecular approaches and more  spe-
iﬁc radiotracers or radiopharmaceuticals are being developed
o identify distinctive tumor characteristics that will translate
nto more  accurate target delineation and enhanced radiation
reatment planning and delivery. Computer technology will
ontinue to grow exponentially6 and to accommodate expand-
ng loads of imaging and computational dosimetry data more
eliance will be placed on cloud computing. Among the ben-
ﬁts of cloud computing are standardization, faster rate of
echnology adoption, promotion of best practices as well as
otentially signiﬁcant cost savings.
Because of existing interobserver variability in target and
ven OAR delineation it will be important to standardize
mage acquisition and interpretation criteria by Radiation
ncologists and Diagnostic Radiologists and foster training
n this ﬁeld. This persistent interobserver and interpracti-
ioner variability despite the continuous improvements and
tandardization in diagnostic and technical capabilities is
ccelerating the need and research in decision support and
nowledge based tools. While such tools have had a varying
egree of acceptance in other areas of medicine, they are still
n infancy in Radiation Oncology and will likely become one
f key clinical and technical areas of interest. This need is fur-
her fueled by the much more  ubiquitous availability of the
ost advanced technologies in areas which historically would
ot have been able to afford such technology. Due to economic
lobalization now these areas and countries can afford the lat-
st technologies but it will take some time for them to be able
o create professional and technical staff which can take the
ull advantage of these technologies and decision support and
nowledge based tools can signiﬁcantly accelerate bridging of
his gap.
Heavy particles and protons, already in clinical use in many
ountries will continue to expand. It will be critical to establish
he potential cost beneﬁt of these modalities and identify the
elected group of patients to be treated with them.
.  Adaptive  radiation  therapy
hereas radiation dose escalation is attractive and in some
ites it has been shown to improve tumor control (i.e. prostate
ancer), the new technological developments are particularly
ttuned to the use of hypofractionated, including stereotac-
ic irradiation, which has not only biological rationale but
deally an impact on resource utilization and the cost of
atient care and convenience. The above advances in com-
utational capability and electronic engineering will amplify
he opportunities to administer Adaptive Radiation Therapy
n a real-time basis, to daily optimize dose, to accommo-
ate anatomical deformation or changes in the volume,therapy 1 8 ( 2 0 1 3 ) 329–332 331
conﬁguration or biological tumor characteristics using auto-
mated segmentation and to correct random or systematic
positioning uncertainties. We envision further reﬁnements in
designing more  versatile and reliable software, remote com-
putational techniques and automation for treatment planning
and delivery, to enhance efﬁciency and safety in the pro-
cesses of radiation therapy. Further, the voluminous amount
of clinical and dosimetry data generated with contemporary
techniques requires a robust processing system, which in the
future will be strengthened with reﬁned informatics and use
of cloud computing for data acquisition, analysis and stor-
age. The advances in speed and scope of imaging technologies
used in radiotherapy, will allow us to quantify anatomical and
biological characteristics of patient anatomy at an increased
frequency and some aspects of this is already used for daily
patient assessments and the scope of these assessments will
continue. It is also likely that there will be a continuation
in increase of image  acquisition during the actual treatment
delivery. These evolutions in imaging capabilities coupled with
fast contour delineation and fast dose computation should
allow us to more  adequately quantify true doses delivered
to target volumes and normal structures and to quantify
their response treatment. The increased availability of such
technology along with cloud based infrastructure should also
accelerate the implementation of these processes for a large
number of patients.
7.  Brachytherapy
Brachytherapy, prime exponent of adaptive radiation therapy,
will incorporate many  of these advances in the management
of suitable patients.7 Other more  exotic area with poten-
tial application in clinical Radiation Oncology is the use of
nanoparticles with speciﬁc target radiotracers for imaging or
radiopharmaceuticals for therapeutic purposes.8
8.  Cost  beneﬁt  and  Comparative
Effectiveness
Because of growing concern world-wide with the ever-
increasing cost of health care and of sophisticated new
technology we  will need to increase our efforts in using cost
beneﬁt and comparative effectiveness techniques to docu-
ment the gains that innovative technology may provide in
patient care.
9.  Need  for  reﬁned  quality  assurance
Complex technology is associated with a potential increased
risk on unintended undesirable effects. We  must remain
extremely vigilant and continuously establish and apply in our
daily practice Quality Assurance Programs that will ensure the
safety of our patients (and colleagues) and enhance the preci-
sion in planning and delivery of radiation therapy, as well as
the reliability of data in clinical trials.9–11
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